FogPharma

FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating mini proteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments.

FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.

It is laser-focused and unstoppable in its mission to deliver a new class of medicines to patients and their families to bring them years to life and life to years.

FogPharma headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Pharmaceutical, Biopharma, Precision Medicine sector. The company focuses on Biotechnology and has secured $76.4B in funding across 144 round(s). With a team of 101-250 employees, FogPharma is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - FogPharma, raised $11.0M. Discover more about their projects, partnerships, and impact on our platform.